CSI Dry Eye Innovations introduced a future-focused brand architecture that serves as the parent brand for current and future offerings. Under this structure, CSI Dry Eye Software remains the company’s primary product, protected by the newly issued patent.

The patent protects the core clinical reasoning framework behind CSI Dry Eye Software. Unlike tools that rely on isolated test results or basic data capture, the patented process analyzes multiple dry eye indicators, determines subtype and severity, and generates explainable, ranked treatment pathways to support clinical decision-making, according to the company. The software does not diagnose autonomously or replace clinician judgment. Instead, it provides standardized, evidence-based structure while preserving full clinical authority.

Additionally, the launch of CSI Dry Eye Innovations includes a refreshed visual identity, a new website coming, and clearer communication of CSI’s role in dry eye care.